Grapefruit USA Inc (GPFT)

[goldcoastoh]

that meeting will only discuss mammo and CAD (computer-aided detection). likely the FDA is going to continue their push for "outcome measures."

which sorta means that okay if something is shown to work now go a little further downstream and tell me - okay now we now it works compared to one thing (whatever) but what might that mean in tne bigger picture...

for example, CAD can be used to assist radiologists in diagnosing breast cancer. thus, it may increase specificity and sensitivity --- but will the increased specificity/sensitivity translate into preventing unnecessary tests or other medical cost during/after workup, etc.

i think the CAD discussion will be broadly based, i.e., not just pertain to mammo.